NEKTAR THERAPEUTICS (NKTR)
US6402681083 - Common Stock
ChartMill assigns a Buy % Consensus number of 47% to NKTR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.04. This target is 58.3% above the current price.
NKTR was analyzed by 9 analysts. The buy percentage consensus is at 47. So analysts seem to be rather neutral about NKTR.
In the previous month the buy percentage consensus was at a similar level.
NKTR was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-06 | Jefferies | Maintains | Hold -> Hold |
| 2023-11-20 | JP Morgan | Reiterate | Underweight |
| 2023-11-09 | TD Cowen | Upgrade | Market Perform -> Outperform |
| 2023-08-07 | Mizuho | Reiterate | Neutral |
| 2023-05-10 | Jefferies | Upgrade | Underperform -> Hold |
| 2023-03-06 | Oppenheimer | Maintains | Perform |
| 2023-02-27 | Goldman Sachs | Maintains | Sell |
| 2023-02-24 | SVB Leerink | Maintains | Market Perform |
| 2023-02-24 | Jefferies | Downgrade | Hold -> Underperform |
| 2022-08-08 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2022-04-18 | Mizuho | Maintains | Neutral |
| 2022-04-18 | SVB Leerink | Maintains | Market Perform |
| 2022-04-18 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2022-03-09 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2021-11-08 | Benchmark | Upgrade | Hold -> Buy |
| 2021-11-08 | SVB Leerink | Maintains | Market Perform |
| 2021-11-05 | Oppenheimer | Maintains | Perform |
| 2021-09-10 | B of A Securities | Initiate | Neutral |
| 2021-08-06 | SVB Leerink | Maintains | Market Perform |
| 2021-06-28 | Stifel | Upgrade | Hold -> Buy |
| 2021-05-10 | SVB Leerink | Maintains | Market Perform |
| 2021-04-06 | SVB Leerink | Maintains | Market Perform |
| 2021-02-22 | Benchmark | Downgrade | Buy -> Hold |